SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

May 13, 2013 07:00 ET

Implant Sciences Ships 8 Explosives Trace Detection Systems to Mexico City International Airport

WILMINGTON, MA--(Marketwired - May 13, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has shipped eight Quantum Sniffer™ QS-H150 handheld explosives trace detectors in a follow-on order to the Mexico City International Airport. The units will be used for aviation security including the screening of hand luggage and passengers at security checkpoints.

Mexico City International Airport, having used Quantum Sniffers for several years, is well aware of the significant advantages of Implant Sciences' systems. The low cost of consumables and maintenance weighed strongly in their decision to purchase additional QS-H150s, as did the system's ease-of-use, which facilitates the training of security personnel. Airport administrators also cited the non-radioactive ion source as providing a safer screening environment for both security personnel and travelers.

"The Mexico City airport uses the QS-H150 all day, every day for security operations. That they came back to us when they needed to expand their screening capability speaks volumes about the systems' performance and reliability," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones. "This reputation is one of the cornerstones of our foundation for continued growth and demand for Quantum Sniffers in the aviation security market."

About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector
The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:
    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact